In a phase I pilot study, the feasibility and efficacy of a DC vaccine pulsed with the Wilms tumor gene-1 (WT1) peptide in combination with GEM were evaluated in the treatment of advanced PC as a first line of treatment. This evidence concerns the gene WT1 and pachyonychia congenita.